Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from EXACT Therapeutics AS ( (DE:56F) ) is now available.
EXACT Therapeutics has announced positive final results from its Phase 1 ACTIVATE trial, which demonstrated that their Acoustic Cluster Therapy (ACT®) significantly enhances the efficacy of chemotherapy in patients with liver metastases of colorectal origin. The trial’s success supports the initiation of a Phase 2 trial in pancreatic cancer, highlighting the potential of ACT technology as a unique and effective treatment option, with a strong safety profile and dose-response relationship.
More about EXACT Therapeutics AS
EXACT Therapeutics is a clinical-stage precision medicine company that leverages ultrasound and microbubbles for targeted drug delivery in oncology. Their proprietary Acoustic Cluster Therapy (ACT®) is designed to enhance the effectiveness of chemotherapy and can be applied across various therapeutic agents in oncology and other medical fields, including brain diseases. The company’s shares are traded on Euronext Growth Oslo.
Average Trading Volume: 8,372
Current Market Cap: NOK189.8M
Find detailed analytics on 56F stock on TipRanks’ Stock Analysis page.